Vanda Pharmaceuticals | VNDA - Current Assets


Vanda Pharmaceuticals reported $347.26M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Akebia Therapeutics USD 243.48M 9.47M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Anika Therapeutics USD 93.56M 9.8M Mar/2026
Arrowhead Research USD 1.84B 665.36M Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Insmed USD 1.61B 181.04M Mar/2026
J&J USD 59.77B 601M Jun/2026
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
Ligand Pharmaceuticals USD 865.42M 33.14M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Moderna USD 5.77B 774M Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Pfizer USD 42.82B 76M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.16B 789M Mar/2026
Takeda JPY 3.09T 25.94B Mar/2026
Teva Pharmaceutical Industries USD 13.71B 236M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025
Veracyte USD 522.17M 33.8M Mar/2026